ZYME [NYSE]
Zymeworks Inc.
Index- P/E- EPS (ttm)-3.63 Insider Own0.10% Shs Outstand66.48M Perf Week-2.68%
Market Cap489.58M Forward P/E- EPS next Y-1.53 Insider Trans-3.71% Shs Float54.49M Perf Month3.53%
Income-224.20M PEG- EPS next Q2.53 Inst Own78.40% Short Float / Ratio17.76% / 9.59 Perf Quarter60.08%
Sales29.90M P/S16.37 EPS this Y-14.70% Inst Trans-0.57% Short Interest9.68M Perf Half Y10.76%
Book/sh2.70 P/B2.82 EPS next Y35.20% ROA-60.30% Target Price12.31 Perf Year-58.79%
Cash/sh2.59 P/C2.94 EPS next 5Y11.00% ROE-96.10% 52W Range4.11 - 19.08 Perf YTD-53.51%
Dividend- P/FCF- EPS past 5Y-24.10% ROI-86.30% 52W High-61.74% Beta1.11
Dividend %- Quick Ratio3.30 Sales past 5Y19.40% Gross Margin- 52W Low77.62% ATR0.57
Employees286 Current Ratio3.30 Sales Q/Q-40.90% Oper. Margin- RSI (14)46.74 Volatility5.97% 7.94%
OptionableYes Debt/Eq0.00 EPS Q/Q38.60% Profit Margin- Rel Volume1.70 Prev Close7.62
ShortableYes LT Debt/Eq0.00 EarningsNov 08 AMC Payout- Avg Volume1.01M Price7.30
Recom2.20 SMA20-7.30% SMA506.97% SMA20014.74% Volume1,292,731 Change-4.20%
Nov-01-22Downgrade H.C. Wainwright Buy → Neutral $40 → $8
Oct-21-22Downgrade SVB Leerink Outperform → Mkt Perform $8
Oct-04-22Resumed Wells Fargo Overweight $45 → $9
May-05-22Upgrade Guggenheim Neutral → Buy $14
Mar-15-22Initiated Evercore ISI Outperform $15
Dec-10-21Upgrade SVB Leerink Mkt Perform → Outperform
Nov-17-21Resumed Guggenheim Neutral
Oct-07-21Initiated Jefferies Hold $32
Mar-31-21Initiated Credit Suisse Outperform $55
Feb-25-21Downgrade SVB Leerink Outperform → Mkt Perform $41
Show Previous Ratings
Dec-05-22 08:30AM
Nov-29-22 08:30AM
Nov-24-22 12:20PM
Nov-22-22 09:55AM
08:30AM
12:22PM Loading…
Nov-21-22 12:22PM
09:55AM
09:00AM
Nov-08-22 05:45PM
04:22PM
Nov-02-22 10:00AM
Nov-01-22 10:01AM
Oct-31-22 04:42PM
Oct-21-22 01:35PM
Oct-20-22 01:36PM
11:48AM Loading…
11:48AM
08:30AM
Oct-19-22 11:08AM
08:38AM
07:29AM
06:07AM
06:00AM
Oct-18-22 08:30AM
Oct-13-22 07:00AM
Oct-07-22 04:15PM
Oct-04-22 08:30AM
Oct-03-22 08:30AM
Sep-29-22 07:30AM
Sep-26-22 04:15PM
Sep-16-22 08:30AM
09:34AM Loading…
Sep-13-22 09:34AM
Sep-08-22 04:15PM
Sep-04-22 06:05PM
Aug-04-22 08:35PM
04:15PM
Aug-01-22 08:30AM
Jul-27-22 08:45AM
Jul-25-22 08:30AM
Jul-22-22 08:30AM
Jul-21-22 08:30AM
Jul-15-22 08:00AM
Jun-27-22 08:30AM
Jun-10-22 09:57AM
09:15AM
May-27-22 09:57AM
05:30AM
May-26-22 05:00PM
May-20-22 03:13PM
09:53AM
09:15AM
May-19-22 01:00PM
May-04-22 06:25PM
04:15PM
May-03-22 03:27PM
02:59PM
May-02-22 08:30AM
06:36AM
Apr-29-22 10:53AM
Apr-28-22 09:00PM
05:15PM
04:39PM
08:30AM
Apr-27-22 04:15PM
03:03PM
Apr-19-22 04:15PM
Apr-14-22 06:40AM
Apr-06-22 09:26AM
Apr-05-22 04:01PM
Apr-01-22 08:30AM
Mar-03-22 08:30AM
Feb-28-22 06:37AM
Feb-24-22 06:20PM
04:15PM
Feb-17-22 03:02PM
Feb-15-22 05:25PM
Feb-08-22 04:15PM
Feb-03-22 04:15PM
Feb-01-22 04:49AM
Jan-31-22 12:05PM
10:00AM
05:33AM
Jan-27-22 09:16AM
Jan-26-22 09:36PM
04:01PM
Jan-20-22 07:02AM
Jan-19-22 04:15PM
Jan-17-22 07:40AM
Jan-15-22 08:30AM
Jan-14-22 10:10AM
06:27AM
Jan-10-22 06:00AM
Jan-06-22 08:30AM
Jan-05-22 04:30PM
Dec-11-21 01:18PM
Dec-09-21 08:30AM
Dec-08-21 06:00PM
Dec-01-21 08:30AM
Nov-22-21 01:53PM
Nov-19-21 09:21AM
Nov-09-21 04:05PM
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It is also advancing a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Josephson NeilChief Medical OfficerNov 10Option Exercise0.005,885016,924Nov 14 09:41 PM
Josephson NeilChief Medical OfficerNov 10Sale8.102,47520,04514,449Nov 14 09:41 PM
Klompas Neil AChief Operating OfficerMar 10Option Exercise0.005,208016,255Mar 11 09:00 PM
Josephson NeilChief Medical OfficerMar 10Option Exercise0.002,39509,514Mar 11 09:00 PM
Klompas Neil AChief Operating OfficerMar 10Sale6.882,97920,49613,276Mar 11 09:00 PM
Josephson NeilChief Medical OfficerJan 07Buy14.285,00071,3867,119Jan 11 09:47 PM